Thank you. Good morning, and welcome to Taysha's TSHA-102 Rett Syndrome Program Update Conference Call. Earlier this morning, we issued a press release announcing the completion of dosing in the REVEAL pivotal trial and longer-term clinical data from Part A of the REVEAL Phase I/II trial evaluating TSHA-102 for the treatment of Rett syndrome. A copy of this press release is available on the company's website. Joining me on today's call are Sean Nolan, Chief Executive Officer; and Su Nagendran, President and ...

Taysha Gene Therapies (NasdaqGS:TSHA) Update / briefing June 22, 2026 08:30 AM ET Speaker7Good day. Thank you for standing by. Welcome to the Taysha Gene 102 Rett syndrome Program Update conference call. At this time, all participants on a listen-only mode. After the speakers' presentation, there'll be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising you that your hand is raised. Pleas ...

TSHA -102 Rett Syndrome program Update: Longer -term Results from REVEAL Phase 1/2 trials June 2026 1 Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the potential of TSHA-102, the durability and reproducibility of the clinical data from the REVEAL trials, the anticipated Part B trial desi ...

Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated with no treatment-related SAEs or DLTs reported as of the June 2026 data cutoff across REVEAL Phase 1/2 and pivotal trials (N=29) 100% of REVEAL Part A patients (N=12, 6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102, with consistent responses across ages and d ...